Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
As well as discovering new therapeutic targets, we also have the ability to continue the drug discovery process by following up with our commercial service offers, in particular DRIVE-IDDS (Small Molecule; Molecular RadioTherapy).
This support will also be provided along with our partners at the FederAIdd Campus and will speed up the process by deploying AI technology at each stage. The AI BU will liaise with our partners and remain your single point of contact up to the clinical phases.